Exicure stock surges 25% after acquiring GPCR Therapeutics' U.S. unit, positive.

From StockTwits: 2025-01-23 07:44:12

Exicure Inc. saw a 25% surge in shares after announcing a strategic acquisition and collaboration deal with GPCR Therapeutics. Exicure will purchase GPCR Therapeutics USA and collaborate on advancing GPCR-related technologies. The deal includes milestone payments tied to clinical trial progress and net sales achievements, as well as a 10% royalty on net sales. Retail interest in Exicure spiked after the announcement, with the company’s stock gaining 265% over the past year. GPCR USA, known for developing cutting-edge treatments like Opdivo and Yervoy, is currently conducting a Phase 2 clinical trial targeting blood cancer patients.



Read more at StockTwits: Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes